What is Protagonist Therapeutics's EV / EBITDA?

Protagonist Therapeutics (PTGX) reported EV / EBITDA of 201.2× in Q3 2025.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Protagonist Therapeutics PTGX EV / EBITDA

EV / EBITDA at other companies

Bristol-Myers SquibbBMY

12×+0.4×

Eli LillyLLY

25.9×-24.4×

AmgenAMGN

15.9×-1.3×

IncyteINCY

9×-28.2×

AbbVieABBV

19.8×—

Regeneron PharmaceuticalsREGN

19.5×+3.6×

Other financials

Income statement

See full

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

See full

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

See full

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

See full

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

See full

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Calculated from Protagonist Therapeutics’s reported figures.

enterprise value/ebitda=201.2×

Based on the most recent quarter.

The official record: Protagonist Therapeutics’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Protagonist Therapeutics's EV / EBITDA?: Protagonist Therapeutics (PTGX) reported EV / EBITDA of 201.2× in Q3 2025.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.